Quest Diagnostics's most recent trend suggests a bearish bias. One trading opportunity on Quest Diagnostics is a Bear Call Spread using a strike $55.00 short call and a strike $65.00 long call offers a potential 6.95% return on risk over the next 32 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $55.00 by expiration. The full premium credit of $0.65 would be kept by the premium seller. The risk of $9.35 would be incurred if the stock rose above the $65.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Quest Diagnostics is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Quest Diagnostics is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Quest Diagnostics
DGX Ups Low-End of 2013 EPS, Restates Revs
Fri, 13 Dec 2013 22:40:04 GMT
Will Quest Diagnostics Have a Happy, Healthy 2014?
Fri, 13 Dec 2013 17:05:00 GMT
Quest Diagnostics Updates Revenue and Adjusted Diluted EPS Guidance for Full-Year 2013
Fri, 13 Dec 2013 12:46:39 GMT
noodls – MADISON, N.J., Dec. 12, 2013 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today updated its estimates for full-year 2013 revenues and …
Bearish play in Quest Diagnostics
Fri, 13 Dec 2013 09:14:12 GMT
Quest Diagnostics Updates Revenue and Adjusted Diluted EPS Guidance for Full-Year 2013
Thu, 12 Dec 2013 22:35:00 GMT
PR Newswire – MADISON, N.J., Dec. 12, 2013 /PRNewswire/ — Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today updated its estimates for full-year 2013 revenues and adjusted diluted earnings per share, on a continuing operations basis and before special items. The company previously updated its full-year 2013 guidance on October 17, 2013. Quest Diagnostics intends to provide guidance for its full-year 2014 in conjunction with its report of 2013 fourth quarter results in January, as is customary for the company. The outlook for adjusted diluted earnings per common share represents management's estimate for the full year 2013 before the impact of the gain on sale of Ibrutinib royalty rights, restructuring and integration charges and loss on sale of the Enterix business. This measure is presented because management believes it is a useful adjunct to the corresponding amount determined under accounting principles generally accepted in the United States since it is meaningful to evaluate the Company's ongoing operating performance and is on a basis consistent with previous estimates of diluted earnings per common share.
Related Posts
Also on Market Tamer…
Follow Us on Facebook